article thumbnail

Digital tools must be used in pharma manufacturing to keep pace with drug discovery and clinical development

pharmaphorum

Digital tools must be used in pharma manufacturing to keep pace with drug discovery and clinical development Mike.Hammerton Thu, 07/03/2024 - 09:43 Bookmark this

article thumbnail

Genenta Science signs manufacturing service deal with AGC Biologics

Pharmaceutical Technology

Genenta Science and AGC Biologics have signed a development and manufacturing service agreement (MSA). Under the deal, AGC Biologics will be responsible for manufacturing the cell therapy lentivirus-based product for the ongoing clinical programmes of Genenta Science.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury

Pharma Mirror

Vectura Group plc, an industry leading inhalation CDMO, today announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide pre-clinical development services for IHL-216A, Incannex’s proprietary inhaled drug product for the treatment of traumatic brain injury (TBI).

article thumbnail

eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service

Pharma Mirror

NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.

article thumbnail

Xenetic Biosciences and Catalent sign deal for cGMP manufacturing

Pharmaceutical Technology

Xenetic Biosciences and Catalent Pharma Solutions have signed an agreement for the cGMP manufacturing of the Xenetic’s recombinant protein, Human DNase I. We are excited to take this step forward on the path to the clinic and look forward to investigating systemic DNase as an adjunctive therapy for locally advanced or metastatic cancers.”.

article thumbnail

Viral Vector Manufacturing: Current Landscape and Opportunities

Roots Analysis

Over the last few decades, various viral vector manufacturing have been developed, optimized and standardized for introduction of therapeutic DNA / gene of interest into a patient’s body / cells.

article thumbnail

RVAC Medicines, A*STAR partner for mRNA manufacturing expertise

Pharmaceutical Technology

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore. Topic sponsors are not involved in the creation of editorial content.